Type: Breast cancer
This project will lay the foundations for possible clinical trials of drugs targeting the ELF5 protein as a way of preventing hormone therapy resistance in breast cancer.
Resistance to endocrine therapies is common, affecting around 40% of people who undergo treatment for breast cancer. Dr Caldon’s team investigated the underlying causes of this resistance.
If the project is successful, it would be one of the first targeted treatments for triple-negative breast cancer, with potential for improved survival rates.
This project is a critical step to expand treatment options and could also pave the way for development of immune therapies for breast cancer.
A team of researchers led by Dr Nicole Verrills has been investigating if a new ‘gene marker’ can predict which breast cancer patients may have poorer treatment outcomes.
Shirley Baxter talks about representing consumers in deciding what research Cancer Council funds.
Professor Robert Baxter and his team have tested a promising new therapy, which can effectively block the growth of triple negative breast cancer by inhibiting two proteins that act as stimulators.
Research has revealed the cost of cancer to the Australian health system to be over $6 billion a year.
This project will provide the critical clinical evidence on the effectiveness of adding progesterone to antiestrogenic therapies in patients with early stage breast cancer.
This research builds on previous findings that the protein MCL-1 acts like a life and death switch for triple negative breast cancer cells.